Merck – One timers and Forex weigh on Merck’s guidance

Date: 2015-07

MRK reported its 2Q 2013 results: the net sales decline by 11% ($11.0b) including negative foreign exchange impact by 3% compared to last year. Company reiterated its 2013 non-GAAP EPS guidance ($3.45 and $3.55) while revised its GAAP EPS to be between $1.84 and $2.05 (previous $1.92-2.16). MRK expects its 2013 revenue to be approximately 5 to 6% lower than last year with foreign exchange accounting for approximately 3% points of the decline. The revenue decline was mainly due to loss of exclusivity of Propecia, Clarinex, Maxalt and Singulair and strengthening of US dollars.

Contact With Us
Join templatemonster at google+
Customized Research
Request Sample